20/20 BIOLABS, INC. Total Liabilities and Equity
20/20 BIOLABS, INC. (AIDX) had Total Liabilities and Equity of $6.12 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-14
- 2026-06-30: Liabilities and Equity $6.12M.
- 2026-03-31: Liabilities and Equity $5.80M.
- 2025-12-31: Liabilities and Equity $4.14M.
- 2024-12-31: Liabilities and Equity $3.58M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $6.12M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $5.80M 10-Q · filed 2026-05-20 |
| 2025-12-31 | $4.14M 10-Q · filed 2026-08-14 |
| 2024-12-31 | $3.58M POS AM · filed 2026-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGENOMICS INC (NEO) | United States | $2.514B | -35.96 |